Lynx Investment Advisory’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Lynx Investment Advisory's BMY Position: Q1 2026 in Review
Lynx Investment Advisory opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 5,473 shares worth $332K. The stake represents 0.16% of the portfolio and ranks #134 among its holdings. This is a return to the name: Lynx Investment Advisory previously reported a position in BMY as recently as Q2 2024.
Lynx Investment Advisory first reported a position in BMY in Q2 2024 and has held it in 2 quarters since. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Lynx Investment Advisory held 5,473 shares of Bristol-Myers Squibb worth $332K as of Q1 2026.
- Bristol-Myers Squibb was a new Lynx Investment Advisory position in Q1 2026.
- Bristol-Myers Squibb made up 0.16% of Lynx Investment Advisory's portfolio in Q1 2026, its #134 holding.
- Lynx Investment Advisory first reported a position in Bristol-Myers Squibb in Q2 2024 and has held it in 2 quarters since.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Lynx Investment Advisory's 13F filing for Q1 2026, filed 24 Apr 2026.